This site is intended for healthcare professionals
Drug news

NICE rejects Erbitux (cetuximab) in draft guidance as a treatment for head and neck cancer.- Merck KGaA

Read time: 1 mins
Last updated:28th Jun 2017
Published:2nd Nov 2016
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest